- Home
- PVL vs ANL Comparison
PVL vs ANL Comparison
Compare PVL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PVL | ANL |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PVL | ANL |
|---|---|---|
| Price | $1.88 | $1.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 76.5K | 17.8K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | ★ 19.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $3,511,891.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.51 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $0.88 |
| 52 Week High | $2.04 | $2.99 |
Technical Indicators
Market Signals| Indicator | PVL | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 36.49 |
| Support Level | $1.82 | $1.32 |
| Resistance Level | $1.83 | $1.59 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 56.25 | 31.12 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.